Latest News
Innovent Biologics, Inc.
- Innovent presents clinical data for bispecific fusion protein IBI363 - Vietnam Investment Review
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
- ESMO26: Takeda, Innovent's gastric cancer ADC cuts risk of death by 43%
- Innovent Biologics, Inc. Estimates – GETTEX:6IB
- ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
- Innovent's Sycume meets phase 3 endpoint for inactive TED
- Innovent's Sycume meets primary endpoint in Phase III trial in inactive thyroid eye disease
- Innovent's Sycume Meets Phase 3 Goal in Inactive Thyroid Eye Disease
- Innovent's Sycume hits Phase III endpoint in Chinese thyroid eye disease trial
- Innovent Sets 2030 Revenue Forecast as GLP-1 and Oncology Treatments Are Main Drivers
- Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
- Innovent Biologics expands Phase 3 lung cancer trial globally - Vietnam Investment Review
Headlines from the last 30 days, linking to the original publishers. See all market news →